SA522433155B1 - مركبات ثلاثية الحلقة مستبدلة - Google Patents
مركبات ثلاثية الحلقة مستبدلةInfo
- Publication number
- SA522433155B1 SA522433155B1 SA522433155A SA522433155A SA522433155B1 SA 522433155 B1 SA522433155 B1 SA 522433155B1 SA 522433155 A SA522433155 A SA 522433155A SA 522433155 A SA522433155 A SA 522433155A SA 522433155 B1 SA522433155 B1 SA 522433155B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- compound
- formula
- rasopathy
- proliferative
- infectious
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
مركبات ثلاثية الحلقة مستبدلة SUBSTITUTED TRICYCLIC COMPOUNDS الملخـــص يتعلق الاختراع الحالي بمركبات الصيغة العامة (I)، في صورتها الصنوانية، أيزومير فراغي، ملح مقبول صيدلانيا منها، متعدد الأشكال، أو تذاوب منها، حيث تكون الحلقة A، الحلقة B، R1 إلى R4، و n كما تم تعريفهم في الوصف التفصيلي، لاستخدامها كمثبطات SOS1 (Son of sevenless homolog 1) في علاج الأمراض أو الاضطرابات التكاثرية، المُعدية وRASopathy (المتلازمات التنموية التي تسببها طفرات السلالة الجرثومية). يتعلق الاختراع أيضًا بطرق لتصنيع مركب الصيغة I، التركيبات الصيدلانية التي تحتوي على مركب الصيغة I، طريقة لعلاج الأمراض أو الاضطرابات التكاثرية، المُعدية وRASopathy، على سبيل المثال، السرطان، من خلال إعطاء المركب المذكور وتركيبات مركب الصيغة I مع المكونات النشطة الأخرى.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921054254 | 2019-12-27 | ||
| IN201921049099 | 2019-12-29 | ||
| IN202021022668 | 2020-05-29 | ||
| IN202021032769 | 2020-07-30 | ||
| IN202021035200 | 2020-08-14 | ||
| PCT/IB2020/062462 WO2021130731A1 (en) | 2019-12-27 | 2020-12-27 | Substituted tricyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA522433155B1 true SA522433155B1 (ar) | 2025-04-20 |
Family
ID=74184675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522433155A SA522433155B1 (ar) | 2019-12-27 | 2022-06-27 | مركبات ثلاثية الحلقة مستبدلة |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20230119316A1 (ar) |
| EP (1) | EP4081521B1 (ar) |
| JP (1) | JP7642647B2 (ar) |
| KR (1) | KR20220132543A (ar) |
| CN (1) | CN115605476B (ar) |
| AU (1) | AU2020412429B2 (ar) |
| BR (1) | BR112022012641A2 (ar) |
| CA (1) | CA3165864A1 (ar) |
| CL (1) | CL2022001739A1 (ar) |
| CO (1) | CO2022010460A2 (ar) |
| CR (1) | CR20220363A (ar) |
| DK (1) | DK4081521T3 (ar) |
| EC (1) | ECSP22058816A (ar) |
| FI (1) | FI4081521T3 (ar) |
| GE (2) | GEP20247653B (ar) |
| HR (1) | HRP20260329T1 (ar) |
| IL (1) | IL294198B1 (ar) |
| LT (1) | LT4081521T (ar) |
| MA (1) | MA58181B1 (ar) |
| MX (1) | MX2022008066A (ar) |
| PE (1) | PE20221283A1 (ar) |
| PH (1) | PH12022551585A1 (ar) |
| PL (1) | PL4081521T3 (ar) |
| PT (1) | PT4081521T (ar) |
| RS (1) | RS67848B1 (ar) |
| SA (1) | SA522433155B1 (ar) |
| SM (1) | SMT202600112T1 (ar) |
| UA (1) | UA130721C2 (ar) |
| WO (1) | WO2021130731A1 (ar) |
| ZA (1) | ZA202207722B (ar) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| MX2021000293A (es) | 2018-07-09 | 2021-07-15 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos antihelminticos. |
| JP7637630B2 (ja) | 2019-03-19 | 2025-02-28 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 駆虫性アザベンゾチオフェンおよびアザベンゾフラン化合物 |
| EP4077309A1 (en) | 2019-12-19 | 2022-10-26 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| PH12022553222A1 (en) | 2020-05-29 | 2024-02-12 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic heterocyclic compounds |
| AU2021345111B2 (en) | 2020-09-15 | 2025-11-27 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| WO2022083657A1 (zh) * | 2020-10-20 | 2022-04-28 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| CN116568681B (zh) * | 2020-12-07 | 2026-01-02 | 北京泰德制药股份有限公司 | Sos1抑制剂、包含其的药物组合物及其用途 |
| CA3203205A1 (en) * | 2021-01-19 | 2022-07-28 | Mandar Ramesh Bhonde | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer |
| CN114835719A (zh) * | 2021-02-01 | 2022-08-02 | 苏州泽璟生物制药股份有限公司 | 取代双环并芳杂环胺类抑制剂及其制备方法和应用 |
| CN115028644A (zh) * | 2021-03-08 | 2022-09-09 | 首药控股(北京)股份有限公司 | Sos1抑制剂杂环化合物 |
| AU2022250712A1 (en) | 2021-03-31 | 2023-10-05 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
| US20240238294A1 (en) | 2021-04-09 | 2024-07-18 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| WO2022222875A1 (zh) * | 2021-04-19 | 2022-10-27 | 昆药集团股份有限公司 | 一种苯并嘧啶三环衍生物及其制备方法和应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| AR127495A1 (es) | 2021-11-01 | 2024-01-31 | Boehringer Ingelheim Vetmedica Gmbh | Compuestos de pirrolopiridazina como antihelmínticos |
| CN120923498A (zh) * | 2021-11-04 | 2025-11-11 | 北京福元医药股份有限公司 | 苄氨基取代的杂多环化合物及其组合物、制剂和用途 |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| KR20240122545A (ko) * | 2021-12-17 | 2024-08-12 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 항종양 활성을 갖는 헤테로고리 화합물 및 그 용도 |
| US20250154147A1 (en) | 2022-01-14 | 2025-05-15 | Jazz Pharmaceuticals Ireland Limited | Novel amine-substituted phthalazines and derivatives as sos1 inhibitors |
| KR20230121208A (ko) * | 2022-02-10 | 2023-08-18 | (주)파로스아이바이오 | Sos1 억제제 및 이의 유도체 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN118715229A (zh) * | 2022-03-03 | 2024-09-27 | 浙江海正药业股份有限公司 | 三环类衍生物及其制备方法和用途 |
| GB202203976D0 (en) | 2022-03-22 | 2022-05-04 | Jazz Pharmaceuticals Ireland Ltd | Tricyclic phthalazines and derivatives as sos1 inhibitors |
| KR20250040894A (ko) | 2022-05-25 | 2025-03-25 | 이케나 온콜로지, 인코포레이티드 | Mek 억제제 및 이의 용도 |
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| EP4688790A1 (en) | 2023-04-07 | 2026-02-11 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| CN118546078A (zh) * | 2024-05-15 | 2024-08-27 | 郑州轻工业大学 | 4-羟基-3-[甲氧羰基（甲基）氨基]苯甲酸甲酯及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1995006648A1 (fr) * | 1993-09-03 | 1995-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Derive d'imidazoquinazoline |
| TW372967B (en) | 1994-12-27 | 1999-11-01 | Kanebo Ltd | 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof |
| WO2004003152A2 (en) | 2002-06-26 | 2004-01-08 | Chiron Corporation | Sos1 inhibitors |
| AU2005214373B2 (en) | 2004-02-19 | 2011-07-28 | Rexahn Corporation | Quinazoline derivatives and therapeutic use thereof |
| WO2008079759A1 (en) | 2006-12-20 | 2008-07-03 | Bristol-Myers Squibb Company | Bicyclic lactam factor viia inhibitors useful as anticoagulants |
| AU2008339351B2 (en) | 2007-12-19 | 2013-02-28 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic derivative |
| WO2009106599A2 (en) | 2008-02-29 | 2009-09-03 | Novartis Ag | Substituted piperidines as therapeutic compounds |
| CN102633812B (zh) * | 2012-04-06 | 2014-11-12 | 中国药科大学 | 噁唑酮并喹唑啉衍生物、制备方法及用途 |
| US10087215B2 (en) | 2013-03-15 | 2018-10-02 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| MY180775A (en) | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| WO2016077793A1 (en) | 2014-11-14 | 2016-05-19 | Children's Hospital Medical Center | Sos1 inhibitors for cancer treatment |
| BR112018003264A2 (pt) * | 2015-08-21 | 2018-09-25 | Aldeyra Therapeutics Inc | conjugados de aldeído e usos dos mesmos |
| WO2017040963A1 (en) | 2015-09-03 | 2017-03-09 | Forma Therapeutics, Inc. | [6,6] fused bicyclic hdac8 inhibitors |
| US10898487B2 (en) * | 2016-12-22 | 2021-01-26 | Boehringer Ingelheim International Gmbh | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| JOP20190221A1 (ar) | 2017-04-05 | 2019-09-23 | Seal Rock Therapeutics Inc | مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها |
| ES2944306T3 (es) * | 2017-12-21 | 2023-06-20 | Boehringer Ingelheim Int | Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1 |
| CA3097231A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| WO2019243823A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Azaheterocyclic small molecule modulators of human sting |
| JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
| EP3930845A1 (en) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
-
2020
- 2020-12-27 MX MX2022008066A patent/MX2022008066A/es unknown
- 2020-12-27 PL PL20842043.0T patent/PL4081521T3/pl unknown
- 2020-12-27 WO PCT/IB2020/062462 patent/WO2021130731A1/en not_active Ceased
- 2020-12-27 EP EP20842043.0A patent/EP4081521B1/en active Active
- 2020-12-27 AU AU2020412429A patent/AU2020412429B2/en active Active
- 2020-12-27 KR KR1020227026096A patent/KR20220132543A/ko active Pending
- 2020-12-27 SM SM20260112T patent/SMT202600112T1/it unknown
- 2020-12-27 PT PT208420430T patent/PT4081521T/pt unknown
- 2020-12-27 PE PE2022001331A patent/PE20221283A1/es unknown
- 2020-12-27 LT LTEPPCT/IB2020/062462T patent/LT4081521T/lt unknown
- 2020-12-27 US US17/789,293 patent/US20230119316A1/en active Pending
- 2020-12-27 CN CN202080097766.XA patent/CN115605476B/zh active Active
- 2020-12-27 GE GEAP202016015A patent/GEP20247653B/en unknown
- 2020-12-27 JP JP2022539232A patent/JP7642647B2/ja active Active
- 2020-12-27 FI FIEP20842043.0T patent/FI4081521T3/fi active
- 2020-12-27 UA UAA202202691A patent/UA130721C2/uk unknown
- 2020-12-27 PH PH1/2022/551585A patent/PH12022551585A1/en unknown
- 2020-12-27 CA CA3165864A patent/CA3165864A1/en active Pending
- 2020-12-27 BR BR112022012641A patent/BR112022012641A2/pt unknown
- 2020-12-27 RS RS20260291A patent/RS67848B1/sr unknown
- 2020-12-27 GE GEAP202416015A patent/GEAP202416015A/en unknown
- 2020-12-27 CR CR20220363A patent/CR20220363A/es unknown
- 2020-12-27 MA MA58181A patent/MA58181B1/fr unknown
- 2020-12-27 DK DK20842043.0T patent/DK4081521T3/da active
- 2020-12-27 HR HRP20260329TT patent/HRP20260329T1/hr unknown
-
2022
- 2022-06-22 IL IL294198A patent/IL294198B1/en unknown
- 2022-06-23 CL CL2022001739A patent/CL2022001739A1/es unknown
- 2022-06-27 SA SA522433155A patent/SA522433155B1/ar unknown
- 2022-07-12 ZA ZA2022/07722A patent/ZA202207722B/en unknown
- 2022-07-26 CO CONC2022/0010460A patent/CO2022010460A2/es unknown
- 2022-07-26 EC ECSENADI202258816A patent/ECSP22058816A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551585A1 (en) | Substituted tricyclic compounds | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| EA201892300A1 (ru) | Макроциклические ингибиторы mcl1 для лечения рака | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. |